P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Completed Genome Sequence of Dechloromonas aromatica: Analysis of a Microbe with Diverse Bioremediative Capability in Anaerobic Environments
John D. Coates,K.V. Kellaris,William S. Feil,Helene Feil,Laurie A. Achenbach,Romy Chakraborty,C. Shang,Eric J. Alm,K. Huang,Morgan N. Price,Keith Keller,Stephan Trong,G. Di Bartolo,Adam P. Arkin,Alla Lapidus,Paul G. Richardson,Frank W. Larimer,Susan M. O'Connor +17 more
TL;DR: Author(s): Coates, J.D.; Kellaris, K.W.; O'Connor, S.M.
Journal ArticleDOI
A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.
Antonio Palumbo,Alessandra Larocca,Cecilia Rus,Davide Rossi,Patrizia Pregno,Patrizia Falco,Ilaria Avonto,Valeria Magarotto,Federica Cavallo,Massimo Iacobelli,Gianluca Gaidano,Constantine S. Mitsiades,Paul G. Richardson,Kenneth C. Anderson,Mario Boccadoro +14 more
TL;DR: In this phase I/II study, the efficacy and feasibility of MPTD in the setting of advanced myeloma patients are confirmed and interestingly a protective role of DF against thrombosis is also suggested.
Journal ArticleDOI
Vaccination with DC/Multiple Myeloma Fusions in Conjunction with Stem Cell Transplantation.
David Avigan,Jacalyn Rosenblatt,Baldev Vasir,Zekui Wu,Adam Bissonnette,Claire MacNamara,Lynne Uhl,Corrine Lenahan,Kenneth B. Miller,James D. Levine,Robin Joyce,Karen Lowe,Dilani Dombagoda,Paul G. Richardson,Kenneth C. Anderson,Nikhil C. Munshi,Donald Kuffe +16 more
TL;DR: Fusion cell vaccination in conjunction with stem cell transplantation has been well tolerated, induced anti-tumor immunity and clinical responses in patients with multiple myeloma and one patient with highly aggressive disease who experienced disease progression in the early post-transplant period, demonstrated initial response and then stabilization of disease with vaccination.
Journal ArticleDOI
Tail-Phase Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in HIV-Uninfected Adults: HPTN 077
Raphael J. Landovitz,Sue Li,Joseph J. Eron,Beatriz Grinsztejn,Halima Dawood,Albert Y. Liu,Manya Magnus,Mina C. Hosseinipour,Ravindre Panchia,Leslie Cottle,Gordon Chau,Paul G. Richardson,Mark A. Marzinke,Susan H. Eshleman,Ryan Kofron,Adeola Adeyeye,David N. Burns,Alex R. Rinehart,David Margolis,Myron S. Cohen,Marybeth McCauley,Craig W. Hendrix +21 more
TL;DR: In this paper, the terminal pharmacokinetics and safety of CAB LA after final injection were investigated as part of a Phase 2 study, where participants were randomized 3:1 to CAB or placebo.
Journal ArticleDOI
A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism
Arghya Ray,Deepika Sharma Das,Yan Song,Vincent Macri,Christopher L. Brooks,Eric K. Rowinsky,Paul G. Richardson,Dharminder Chauhan,Kenneth C. Anderson +8 more
TL;DR: The data provide the basis for using SL-401 to directly target pDCs and inhibit the pDC-MM interaction as well as target osteolytic bone disease in novel therapeutic strategies and enhance both anti-tumor immunity and cytotoxicity.